Phase 2 Review for Zoetis’ proposed acquisition of Neogen Genomics

accc
Written By Julie Clarke

The ACCC has announced that Zoetis Holdings LLC’s proposed acquisition of Neogen Corporation’s global animal genomic testing business (Neogen Genomics) could substantially lessen competition and requires Phase 2 review.

View ACCC media release.

View ACCC Acquisitions register.

See my phase 2 review page.

Julie Clarke
Previous

ACCC publishes FY25/26 data on the new merger control regime
Next

Coles applies for review of ACCC determination opposing acquisition of Kalgoorlie supermarket and liquor site